Trial Profile
Retrospective Study of the Safety and Mogamulizumab for relapsed ATL after Allogeneic Hematopoietic Cell Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Aug 2018
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary)
- Indications T-cell leukaemia
- Focus Therapeutic Use
- 23 Aug 2018 New trial record
- 16 Aug 2018 Results published in the Bone Marrow Transplantation